BioSante Pharmaceuticals (BPAX) announces positive Phase 1 results from a clinical study of its...

|By:, SA News Editor

BioSante Pharmaceuticals (BPAX) announces positive Phase 1 results from a clinical study of its GVAX prostate cancer vaccine, with an indication patients responded favorably to the treatment. Shares +7.8% premarket.